To test the ability of the DC subsets in relaying CD4+ T-cell help for CD8+ T-cell priming, we established an in vitro tumor antigen-specific CTL priming platform using the primary DC subsets, CD4+- and CD8+ T-cells purified from human blood (Fig. 2b). This evidence concerns the gene CD4 and neoplasm.